Buchang Pharmaceutical (603858.SH) subsidiary signs two technology development contracts

Zhitong Finance App News, Buchang Pharmaceutical (603858.SH) announced that on July 23, 2026, Baoding Tianhao Pharmaceutical Co., Ltd. (“Baoding Tianhao”), a wholly-owned subsidiary of the company, signed two “technology development (contract) contracts” with Beijing Xinliyan Biotechnology Co., Ltd. (“Beijing Xinliyan”) to entrust Beijing Xinliyan to carry out cooperation in the development, registration and contract production of injectable silicin fillers and injectable calcium hydroxyphosphate fillers. Both products are national Class III medical devices.

According to reports, the indications for injectable silk protein fillers are loss of facial volume during treatment, and the indication for injectable calcium hydroxyphosphate fillers is to treat loss of mandibular edge contours. This time, Baoding Tianhao signed a “Technology Development (Outsourcing) Contract” with a third party, which is conducive to enhancing the company's product development capabilities, expanding the scope of product development, saving the time and cost of clinical trials of the company's products to a certain extent and ensuring the smooth progress of the project.